ICA 105665

Drug Profile

ICA 105665

Alternative Names: ICA-105665

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Icagen
  • Developer Icagen, Inc.; XRpro Sciences
  • Class Antiepileptic drugs; Non-opioid analgesics; Small molecules
  • Mechanism of Action KCNQ potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurological disorders
  • No development reported Epilepsy; Pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pain in United Kingdom (PO, Tablet)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pain in USA (PO, Tablet)
  • 31 Jul 2015 No recent reports on development identified - Phase-II for Epilepsy in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top